Financiación

Investigador/a: Xabier Aguirre Ena

9 financiaciones - 1.457.024€

datos disponibles desde el año 2018

2022

TERAPIA BASADA EN NANOTRANSPORTADORES DE RNA PARA EL TRATAMIENTO DEL CANCER - NanoRC
143.965,00
Identification of the epigenomic and transcriptomic alterations in the transformation of benign monoclonal gammapathies to symptomatic multiple myeloma.
149.985,00
REMANENTES: Deciphering the epigenomic mechanisms of transformation from benign monoclonal gammopathies to symptomatic multiple myeloma
72.924,00

2021

TOWARDS A NEW PARADIGM IN THE TREATMENT OF BLADDER CARCINOMA: THE COMBINATION OF AN EPIGENETIC AGENT AND AN IMMUNE CHECKPOINT INHIBITOR
180.000,00

2020

Deciphering the role of transcription factors as chromatin modulators and drivers of lymphoid neoplasm
101.875,00

2019

Precision medicine approach to target deregulated metabolism in multiple mieloma (PREMAMM)
121.500,00

2018